AT-533

Research use only, not for human use.

AT-533 is a potent inhibitor of Hsp90 and HSV. AT-533 blocks the HIF-1α/VEGF/VEGFR-2 signaling pathway, leading to suppress tumor growth and angiogenesis.

AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including Akt/mTOR/p70S6K, Erk1/2 and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs).

Cell Viability Assay Cell Line:Human umbilical vein endothelial cells (HUVECs): MCF-7 and MDA-MB-231 Concentration:0, 5.6, 16.7, 50, 150, 450, and 1350 nM Incubation Time:12 h, 24 h, 48 h, and 72 h Result:Inhibited cell viability at 48 h with an IC50 value of 50.1 nM. Western Blot Analysis Cell Line:MCF-7 cells and MDA-MB-231 cells Concentration:5 nM, 10 nM, 50 nM, and 75 nM Incubation Time:24 h Result:Inhibited the phosphorylation of VEGF-2, Akt, mTOR, Erk1/2, FAK.

Animal Model:Male C57BL/6 mice with MDA-MB-231 breast cancer xenografts Dosage:10 mg/kg;Administration:Intraperitoneal injection; once daily for 21 days Result:Significantly downregulated HIF-1α and VEGF expression.

——

Cytoskeleton/Cell Adhesion Molecules

HSP

HSP | HSV

——

——

908112-37-8

410.51

C23H30N4O3

>98% (HPLC)

In Vitro:?DMSO : 33.33 mg/mL (81.19 mM; Ultrasonic (<60°C)

Cc1nn(c2CC(C)(C)CC(=O)c12)-c1ccc(C(N)=O)c(N[C@H]2CC[C@H](O)CC2)c1

——

(-20℃)

With Ice Pack

≥ 2 years